Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Suite 100, 2970 Wilderness Place BOULDER CO 80301 |
Tel: | 1-212-9152568 |
Website: | https://www.biodesix.com |
IR: | See website |
Key People | ||
Scott Hutton President, Chief Executive Officer, Director | Robin Harper Cowie Chief Financial Officer, Treasurer, Secretary | Christopher Vazquez Chief Accounting Officer |
Business Overview |
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. |
Financial Overview |
For the fiscal year ended 31 December 2023, Biodesix Inc revenues increased 28% to $49.1M. Net loss decreased 20% to $52.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects (Loss) gain on debt extinguishments, net decrease from $7M (expense) to $0K, Research and development - Balancing v decrease of 24% to $9.7M (expense). |
Employees: | 217 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $155.57M as of Dec 31, 2023 |
Annual revenue (TTM): | $49.09M as of Dec 31, 2023 |
EBITDA (TTM): | -$37.97M as of Dec 31, 2023 |
Net annual income (TTM): | -$52.15M as of Dec 31, 2023 |
Free cash flow (TTM): | -$45.93M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $8.99M as of Dec 31, 2023 |
Shares outstanding: | 113,627,715 as of Apr 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |